3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
58
Unknown
55
Not yet recruiting
41
Completed
30
Active not recruiting
18
Terminated
8
Withdrawn
3
Enrolling by invitation
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Esophageal Squamous Cell Carcinoma
1
Interventions
Drug Therapy
4
Cisplatin
4
Chemoradiotherapy
4
lenvatinib
3
camrelizumab
3
Specimen Handling
3
Paclitaxel
3
Oxaliplatin
3
Carboplatin
3
toripalimab
2
Surgical Procedures, Operative
2
Standard of Care
2
Radiotherapy
2
Patient Navigation
2
Methods
2
Leucovorin
2
Laparoscopy
2
Fluorouracil
2
Fluorodeoxyglucose F18
2
Educational Status
2
Early Intervention, Educational
2
Capecitabine
2
Biopsy
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
tislelizumab
1
sintilimab
1
pembrolizumab
1
nimotuzumab
1
irinotecan sucrosofate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Enrolling by invitation
×
tislelizumab
×
Gastrointestinal
×
Clear all
NCT06303583
2024-03-12
CRIS
Zhejiang Cancer Hospital
Phase 1/2
Enrolling by invitation
30 enrolled